Table 2.
Proportion of patients with ≥50% improvement in MPN‐SAF TSS‐C and individual symptoms at Week 16a
| Symptom, n/N b (%) | Ruxolitinib | HC | P value OR (95% CI) |
|---|---|---|---|
| Primary endpoint | |||
| TSS‐C | 23/53 (43·4) | 16/54 (29·6) |
0·139 1·82 (0·82–4·04) |
| Individual symptoms | |||
| Tiredness | 20/50 (40·0) | 14/53 (26·4) |
0·143 1·86 (0·81–4·27) |
| Itching | 26/48 (54·2) | 16/50 (32·0) |
0·027 2·51 (1·10–5·71) |
| Muscle aches | 18/47 (38·3) | 15/49 (30·6) |
0·428 1·41 (0·60–3·28) |
| Night sweats | 20/42 (47·6) | 20/48 (41·7) |
0·571 1·27 (0·55–2·93) |
| Sweats while awake | 23/42 (54·8) | 16/46 (34·8) |
0·059 2·27 (0·96–40·38) |
HC, hydroxycarbamide; OR, odds ratio; MPN‐SAF TSS C, Myeloproliferative Neoplasm Symptom Assessment Form total symptom score cytokine symptom cluster.
a
For individual symptoms within the TSS C cluster, all patients with a score >0 at baseline were included in the analysis. If the baseline score was 0 and Week 16 score was >0, the patient was considered a nonresponder. If the baseline and Week 16 scores were both 0, the patient was excluded from the responder analysis.
b
The denominator is the number of evaluable patients.